The CCC (CTN222) is a prospective multicentre study recruiting co

The CCC (CTN222) is a prospective multicentre study recruiting coinfected patients from existing

HIV clinic populations at 16 centres across five Canadian provinces (Fig. 1). The cohort was initiated in 2003 in Montreal, Quebec, and then was expanded to other urban and semi-urban centres in 2007. As of October 2010, 955 patients were enrolled. Details on the cohort PD-1 antibody design and protocol are reported elsewhere [9]. Eligible patients were adults aged over 16 years with documented HIV infection [enzyme-linked immunosorbent assay (ELISA) with western blot confirmation] and with chronic HCV infection or evidence of HCV exposure (e.g. HCV-seropositive by ELISA with recombinant immunoblot assay version II (RIBA II) or encoded antigen/enzyme immuno assay (EIA) confirmation, Doxorubicin purchase and/or HCV RNA positive). All potentially eligible patients were invited to participate to avoid selection bias. Patients who initially refused were eligible to enrol in future. The study was approved by the community advisory committee of the Canadian Institutes of Health Research (CIHR)-Canadian HIV Trials Network and by all institutional ethics boards of participating centres. Patients received $15 per visit to compensate for out-of-pocket expenses. After providing informed consent, each participant underwent an initial evaluation followed by study visits approximately every 6 months. Sociodemographic, behavioural, medical and treatment data

were collected using a standardized questionnaire in either English or French. Questionnaires were self-completed or completed with the assistance of a research assistant/nurse. Standard instruments were used to measure quality of life (EQ-5D™) [10]. Additionally, charts were abstracted by research personnel to obtain historical data such as nadir CD4 T-cell count, HIV RNA and all prior HIV and HCV treatment histories and diagnoses. Treatment and diagnostic data were updated

by research personnel at each follow-up visit. At baseline and each subsequent visit, laboratory assessments were performed, including complete blood count, serum chemistry, liver profile, Inositol monophosphatase 1 plasma HIV RNA, absolute and relative CD4 lymphocyte counts and plasma HCV RNA. The duration of HCV infection was determined using the date of HCV seroconversion, if known, or the year of first injecting drug use (IDU) or blood product exposure as a proxy of HCV infection [11]. ART was defined as taking at least three antiretrovirals concurrently. AIDS diagnoses were defined according to the Centers for Disease Control and Prevention classification (e.g. not by CD4 cell criteria alone) [12]. The aspartate aminotransferase (AST) to platelet ratio index (APRI) was used as a noninvasive surrogate for liver fibrosis and defined as: 100 × (AST/upper limit of normal)/platelet count (109/L) [13, 14]. An APRI score > 1.5 was considered to indicate significant fibrosis (corresponding to a biopsy score > F2) [14].

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>